Gujarat Kidney acquires 51% stake in Blue Tree Clinics LLC, UAE

Gujarat Kidney and Super Speciality Limited announced on July 9, 2026, that its Board of Directors has approved the acquisition of a 51% majority stake in Blue Tree Clinics LLC, a polyclinic licensed in Dubai, United Arab Emirates. The transaction, valued at ₹19,83,64,500, will be executed through a Share Purchase Agreement with consideration paid in two tranches over a maximum period of 50 days. This strategic move marks the company's expansion into international healthcare operations, specifically into a new geography and a set of services not currently provided in India.

Acquisition of Blue Tree Clinics LLC

Blue Tree Clinics LLC, incorporated on February 27, 2012, operates in the Medical Services sector. The entity is engaged in Plastic Surgery, Laser Cosmetic, General Dental Clinic, and Chiropractic Centre services. The target entity currently has three shareholders, with one holding 91.866% and two holding 8.114% of the equity. The acquisition is not a related party transaction, and no promoter, promoter group, or group companies hold any interest in the entity being acquired.

The following table summarises the key details of the acquisition:

Parameter:	Details
Target Entity:	Blue Tree Clinics LLC
Country of Incorporation & Operations:	UAE (Dubai)
Date of Incorporation:	February 27, 2012
Industry:	Medical Services
Stake Acquired:	51%
Cost of Acquisition:	₹19,83,64,500/-
Nature of Consideration:	Cash
Payment Structure:	2 tranches, maximum 50 days
Regulatory Approvals Required:	None
Related Party Transaction:	Not Applicable

Blue Tree Clinics LLC — Financial Performance

The target entity reported a Gross Revenue of 10,538,978 AED and a Net Profit of 31,38,809 AED during FY 2025. The company's revenue trend over the last three fiscal years is presented below:

Fiscal Year:	Gross Revenue (AED)
FY 2023:	11,249,500
FY 2024:	9,068,150
FY 2025:	10,538,978

Board Appointment — Additional Independent Director

The Board approved the appointment of Mr. Paresh Dhoti (DIN: 11802188) as an Additional Non-Executive Independent Director, not liable to retire by rotation, with effect from July 9, 2026. The appointment is for a first term of five consecutive years, subject to approval by the members of the company at the next Annual General Meeting.

Key details of the appointment are as follows:

Parameter:	Details
Name:	Mr. Paresh Dhoti
DIN:	11802188
Designation:	Additional Non-Executive Independent Director
Effective Date:	July 9, 2026
Term:	Five consecutive years (first term)
Relationship with Other Directors:	Not related to any Director of the Company

Mr. Paresh Dhoti obtained his Bachelor of Dentistry in 2006 from Government Medical College, Ahmedabad, and has been practicing independently as a Dentist in Vadodara for the last 18 years.

Postal Ballot for IPO Object Variation

The Board also resolved to conduct a postal ballot seeking shareholder approval by way of Special Resolution for a Variation in Objects of the IPO. A separate intimation regarding the postal ballot will be filed in due course. The Board meeting commenced at 4:30 P.M. and concluded at 8:00 P.M. on July 9, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.07%	-3.17%	-1.50%	+25.11%	+21.73%	+21.73%

Gujarat Kidney and Super Speciality Limited has clarified a typographical error concerning the signing date of its Standalone Financial Statements for Q1FY26. The company confirmed that the actual date of signing by authorised signatories was 28-May-2025, correcting the discrepancy observed by the exchange. The entity stated that this clerical error has no bearing on the financial figures, disclosures, or the substance of the results submitted on 28-May-2026.

The company undertook to publish the corrected Standalone Financial Statements with the accurate signing date on its website. It further assured the exchange that appropriate internal checks would be implemented to prevent the recurrence of such errors in future submissions. The clarification was submitted in response to a communication from the National Stock Exchange of India Limited dated 25/06/2026.

Financial Performance Overview

The financial results for the period ended 31 March 2026 were reviewed by the Audit Committee and approved by the Board. The statutory auditor, M/s Y M Shah & Co., issued an unmodified limited review report. The company reported a total income of ₹969.38 lacs for the quarter ended 31 March 2026, compared to ₹805.73 lacs in the corresponding period of the previous year.

For the full year ended 31 March 2026, the company recorded a total income of ₹4,059.47 lacs, an increase from ₹3,528.11 lacs in the previous year. Profit after tax for the year stood at ₹990.14 lacs, up from ₹910.90 lacs in FY25. The earnings per equity share (basic and diluted) for the year were reported at ₹1.59, compared to ₹1.79 in the prior year.

Key Financial Metrics

Particulars	Quarter Ended 31 March 2026 (₹ in Lacs)	Year Ended 31 March 2026 (₹ in Lacs)
Revenue From Operations	924.32	4,010.02
Total Income	969.38	4,059.47
Total Expenses	883.66	2,804.77
Profit Before Tax	85.72	1,254.70
Profit After Tax	136.78	990.14
Total Comprehensive Income	140.76	999.26

Balance Sheet Highlights

The balance sheet as at 31 March 2026 reflects a total asset base of ₹26,607.67 lacs, a significant rise from ₹4,907.22 lacs in the previous year. This increase was primarily driven by a surge in investments, which grew to ₹10,857.85 lacs from ₹151.45 lacs. Total equity also increased substantially to ₹24,645.86 lacs, bolstered by an issue of equity shares amounting to ₹25,079.56 lacs during the year as per the cash flow statement.

Current assets improved to ₹7,163.97 lacs, supported by bank balances of ₹4,172.07 lacs and cash and cash equivalents of ₹741.56 lacs. On the liabilities side, current borrowings stood at ₹1,296.20 lacs, while lease liabilities were recorded at ₹311.60 lacs in total.